Cyclooxygenase-2 in the Pathogenesis of Murine Cerebral Malaria

Journal of Infectious Diseases

Volumn 189, Issue 4, 2004, Pages 751-758

  Ball, Helen J ^a   MacDougall, Hamish G ^a,b   McGregor, Iain S ^a   Hunt, Nicholas H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MALARIA; BRAIN REGION; CONTROLLED STUDY; MALARIA; MOUSE; NONHUMAN; PATHOGENESIS; PLASMODIUM BERGHEI; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; TREATMENT FAILURE;

ANIMALS; BASE SEQUENCE; BRAIN; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; DNA PRIMERS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; ISOENZYMES; MALARIA, CEREBRAL; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 1442324862     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/381503     Document Type: Article

References (38)

1. de Souza JB, Riley EM. Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect 2002; 4:291-300.
2. Neill AL, Chan-Ling T, Hunt NH. Comparisons between microvascular changes in cerebral and non-cerebral malaria in mice, using the retinal whole-mount technique. Parasitology 1993; 107:477-87.
3. Berendt AR, Turner GDH, Newbold CI. Cerebral malaria: the sequestration hypothesis. Parasitol Today 1994; 10:412-4.
4. Clark IA, Rockett KA. The cytokine theory of human cerebral malaria. Parasitol Today 1994; 10:410-2.
5. Clark IA, Rockett KA, Cowden WB. Proposed link between cytokines, nitric oxide and human cerebral malaria. Parasitol Today 1991; 7:205-7.
6. Clark IA, Cowden WB. Why is the pathology of falciparum worse than that of vivax malaria? Parasitol Today 1999; 15:458-61.
7. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development Oncogene 1999; 18:7908-16.
8. Buttgereit F, Burmester GR, Simon LS. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am J Med 2001; 110(Suppl 3A):13S-9S.
9. Perkins DJ, Kremsner PG, Weinberg JB. Inverse relationship of plasma prostaglandin E2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria. J Infect Dis 2001; 183:113-8.
10. English M, Marsh V, Amukoye E, Lowe B, Murphy S, Marsh K. Chronic salicylate poisoning and severe malaria. Lancet 1996; 347:1736-7.
11. Deininger MH, Kremsner PG, Meyermann R, Schluesener HJ. Focal accumulation of cyclooxygenase-1 (COX-1) and COX-2 expressing cells in cerebral malaria. J Neuroimmunol 2000; 106:198-205.
12. Xiao L, Patterson PS, Yang C, Lal AA. Role of eicosanoids in the pathogenesis of murine cerebral malaria. Am J Trop Med Hyg 1999; 60:668-73.
13. Woolley DW, White AGC. Production of thiamine deficiency disease by the feeding of a pyridine analogue of thiamine. J Biol Chem 1943; 149:285-9.
14. Neill AL, Hunt NH. Pathology of fatal and resolving Plasmodium berghei cerebral malaria in mice. Parasitology 1992; 105:165-75.
15. Thumwood CM, Hunt NH, Clark IA, Cowden WB. Breakdown of the blood-brain barrier in murine cerebral malaria. Parasitology 1988; 96: 579-89.
16. Blanco JC, Contursi C, Salkowski CA, DeWitt DL, Ozato K, Vogel SN. Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon γ-dependent cyclooxygenase 2 expression. J Exp Med 2000; 191:2131-44.
17. Jobin C, Morteau O, Han DS, Balfour Sartor R. Specific NF-κB blockade selectively inhibits tumour necrosis factor-α-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology 1998; 95:537-43.
18. Mifflin RC, Saada JI, Di Mari JF, Adegboyega PA, Valentich JD, Powell DW. Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am J Physiol Cell Physiol 2002; 282:C824-34.
19. Scali C, Giovannini MG, Prosperi C, Bellucci A, Pepeu G, Casamenti F. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience 2003; 117:909-19.
20. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997; 17:2746-55.
21. Pompl PN, Ho L, Bianchi M, McManus T, Qin W, Pasinetti GM. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 2003; 17:725-7.
22. Kelley KA, Ho L, Winger D, et al. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol 1999; 155:995-1004.
23. Kunz T, Oliw EH. The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur J Neurosci 2001; 13:569-75.
24. Baik EJ, Kim EJ, Lee SH, Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res 1999; 843:118-29.
25. Sliwa K, Grundmann HJ, Neifer S, et al. Prevention of murine cerebral malaria by a stable prostacyclin analog. Infect Immun 1991; 59:3846-8.
26. Weston MJ, Jackman N, Rudge C, et al. Prostacyclin in Falciparum malaria [letter]. Lancet 1982; 2:609.
27. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5:698-701.
28. Okamoto H, Ito O, Roman RJ, Hudetz AG. Role of inducible nitric oxide synthase and cyclooxygenase-2 in endotoxin-induced cerebral hyperemia. Stroke 1998; 29:1209-18.
29. Weiss HJ, Turitto VT. Prostacyclin (prostaglandin 12, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood 1979; 53:244-50.
30. Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N. Cyclooxygenase-2- issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002; 168:2255-63.
31. Schwenger P, Alpert D, Skolnik EY, Vilcek J. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IκBα phosphorylation and degradation. Mol Cell Biol 1998; 18:78-84.
32. Clark I, Whitten R, Molyneux M, Taylor T. Salicylates, nitric oxide, malaria, and Reye's syndrome. Lancet 2001; 357:625-7.
33. Clark IA, Awburn MM, Whitten RO, et al. Tissue distribution of migration inhibitory factor and inducible nitric oxide synthase in falciparum malaria and sepsis in African children. Malar J 2003; 2:6.
34. Maneerat Y, Viriyavejakul P, Punpoowong B, et al. Inducible nitric oxide synthase expression is increased in the brain in fatal cerebral malaria. Histopathology 2000; 37:269-77.
35. Kremsner PG, Nussler A, Neifer S, et al. Malaria antigen and cytokine-induced production of reactive nitrogen intermediates by murine macrophages: no relevance to the development of experimental cerebral malaria. Immunology 1993; 78:286-90.
36. Favre N, Ryffel B, Rudin W. The development of murine cerebral malaria does not require nitric oxide production. Parasitology 1999; 118:135-8.
37. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15:2057-72.
38. Niederberger E, Tegeder I, Vetter G, et al. Celecoxib loses its antiinflammatory efficacy at high doses through activation of NF-κB. FASEB J 2001; 15:1622-4.